Current News

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to Nuformix plc (LSE:NFX), a pharmaceutical development company and drug repurposing specialist. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, differentiated from the original (by way of dosage, delivery route or presentation), creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are thrilled to be working with Nuformix CEO, Dr Anne Brindley, to help propel the Company’s growth and business development in their drive to address unmet clinical needs in fibrosis and oncology. It is an important time for Nuformix and there is great potential and value in Company’s assets, which have both strong therapeutic and commercial advantages.”

For more information visit the Company’s website: https://nuformix.com/

For further information please contact:

About Walbrook PR:                                                                                                                                            www.walbrookpr.com

Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.

Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.

Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.